Physician profile
Amy B Keefe
NPI 1508890096
$3,611.37
in general payments reported to CMS, 2019-2025
22 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $918 · 2023: $1,405 · 2024: $898 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.79 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $991.05 | 2021-2025 | Otezla, Tavneos, Enbrel |
| Abbvie INC. | $421.12 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $381.99 | 2022-2025 | |
| Janssen Biotech, INC. | $307.26 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $235.60 | 2022-2025 | Taltz |
| Sobi, INC | $209.96 | 2022-2024 | |
| Ucb, INC. | $188.86 | 2022-2024 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $182.71 | 2021-2025 | Benlysta |
| Pfizer INC. | $143.47 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $75.69 | 2022-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $64.14 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.55 | 2023-2024 | Cyltezo |
| Genzyme Corporation | $55.52 | 2024 | |
| Aurinia Pharma U.S., INC. | $53.30 | 2023-2025 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $48.99 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $47.26 | 2023-2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $33.58 | 2024 | Orencia |
| Takeda Pharmaceuticals U.S.A., INC. | $29.67 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.70 | 2025 | Uptravi |
| Ultragenyx Pharmaceutical INC. | $22.58 | 2023 | Crysvita |
| Alexion Pharmaceuticals, INC. | $17.31 | 2025 | Ultomiris |
| Genentech USA, INC. | $16.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Keefe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.